Product Image

Contributor Information

  • Name Simon Langdon
  • Institute Cancer Research UK Edinburgh Centre

Tool Details

  • Tool name: PEO1-CDDP Cell Line
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: PEO1
  • Organism: Human
  • Tissue: Ovary
  • Cancer type: Adenocarcinoma
  • Disease: Cancer
  • Model: Cisplatin Resistance
  • Description: The PEO1-CDDP Cell Line is an in-vitro model to understand the changes in EGF signalling after the onset of cisplatin resistance. Coupled with this change in drug sensitivity, this model also has a modified responsiveness to ligands of the erbB receptor family. This model will be helpful in studying the changes in cellular signalling after drug treatment, which are currently attracting a great deal of interest and this model will be of particular relevance when cytotoxic therapy is combined with signalling inhibitors. Cisplatin Resistance
  • Research area: Cancer; Cell signaling and signal transduction; Drug development
  • Production details: The PE01CDDP cell line was established by in vitro exposure of the PE01 line to cisplatin commencing at 25 nmol/L cisplatin and increasing to 1 Amol/L over a period of 4 months. The resistant cell line thus obtained was then passaged in the absence of cisplatin for a further 4 months to ensure that the resistance remained stable. PEO1 CDDP is from the same patient as the PEO1, PEO4 and PEO6 cell lines (ECACC Catalogue numbers 10032308, 10032309 & 10032310).
  • Cellosaurus ID: CVCL_Y032

  • For Research Use Only

Target Details

  • Target: Human ovarian cancer; oestrogen receptor, drug resistance, cisplatin resistance

Application Details


  • Format: Frozen
  • Growth medium: RPMI 1640 containing 10% heat-inactivated FCS, penicillin (100 units/mL), and streptomycin (100 ug/mL). Cells were maintained routinely at 37?‚°C in a humidified atmosphere of 5% CO2 in air.
  • Temperature: 37C
  • Atmosphere: 5% CO2
  • Shipping conditions: Dry ice



  •   Macleod et al. 2005. Cancer Res. 65(15):6789-800. PMID: 16061661.
  •   Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.